title: WES of Blood: multiple primary lung adenocarcinoma patient-01
design: WES was performed by Novogene Bioinformatics Technology Co., Ltd. (Beijing, China). The exome sequences were captured from 0.4 g of genomic DNA using the Agilent SureSelect Human All Exon V6 kit (Agilent, USA) following the manufacturer's instructions. Initially, the genomic DNA was fragmented using the Covaris LE220R-plus instrument (Covaris, USA). Subsequently, the DNA fragments underwent end repair, phosphorylation, and were added A-tailing and ligated at the 3' ends using paired-end adapters. DNA fragments were selectively enriched in a PCR reaction. Following the PCR reaction, the libraries hybridized with biotin-labeled probes, and the exons of genes were then captured and added index tags. The products were purified using the AMPure XP system (Beckman Coulter, Beverly, USA), and the libraries were assessed for size distribution using the Agilent 5400 system (AATI) (Agilent, USA) and quantified using real-time PCR (Life Technologies, USA) (1.5 nM).The qualified libraries were combined and sequenced on Illumina platforms using the PE150 strategy at Novogene Bioinformatics Technology Co., Ltd. (Beijing, China), based on the effective library concentration and the required data amount.